Related Experiment Videos
Human melanoma antigens recognized by T lymphocytes
Y Kawakami1, P F Robbins, S A Rosenberg
1Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1502, USA.
The Keio Journal of Medicine
|June 1, 1996
Summary
Researchers identified melanoma antigens and T-cell epitopes crucial for cancer immunotherapy. These findings advance understanding of anti-tumor immunity and autoimmune responses against melanocytes, aiding melanoma treatment development.
Area of Science:
- Immunology
- Oncology
- Dermatology
Background:
- Human melanoma antigens recognized by T cells are classified into melanocyte-specific, cancer-testis, mutated, and other proteins.
- Some melanoma epitopes exhibit low HLA-A2 binding affinity, suggesting subdominant or cryptic self-determinant roles.
Purpose of the Study:
- To identify human melanoma antigens and their T-cell epitopes for immunotherapy development.
- To investigate the role of autoreactive T cells in melanoma regression and tumor rejection.
Main Methods:
- Classification of melanoma antigens based on expression patterns.
- Analysis of HLA-A2 binding affinity of melanoma epitopes.
- Induction of melanoma-reactive cytotoxic T lymphocytes (CTLs) from peripheral blood lymphocytes (PBLs).
Main Results:
- Identified melanoma antigens and epitopes, including MART-1, gp100, tyrosinase, TRP-1, MAGE, and mutated proteins.
- Observed a correlation between vitiligo and IL2-based immunotherapy, suggesting autoreactive T cells in melanoma regression.
- Demonstrated tumor regression following adoptive transfer of CTLs recognizing specific epitopes, supporting their role as tumor rejection antigens.
Conclusions:
- Identified melanoma antigens and epitopes are valuable for developing novel immunotherapies for metastatic melanoma.
- These findings enhance understanding of anti-tumor immune responses and autoimmune disorders targeting melanocytes.
- Melanoma-reactive CTLs can be efficiently induced for potential adoptive transfer protocols.